Clinical study on the effectiveness of three products in the treatment of herpes simplex labialis
- Conditions
- B00.1Herpesviral vesicular dermatitis
- Registration Number
- DRKS00007786
- Lead Sponsor
- Sylphar NV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 180
Male and female patients in the age of 18 till 65 years
Written approval of the participant person after clarification
Healthy probands, Probands with a finished therapy, without a hurtful tooth or mucosa illness
Acute Herpes Simplex labialis
Signs that the patient is unable to comply with the test plan (eg lack of cooperation)
Probands with severe general medical disorders
The taking of antibiotic or antiphlogistic drugs in the last two weeks prior to study entry
The taking of anti-inflammatory drugs during the study period
oral diseases, for example Ulcerative gingivitis (NUG), periodontitis colitis (NUP)
Immune systeme disorders
Known hypersensitivity to the substances used in the study
Pregnangcy or lactation
Alcohol or drug abuse in the recent past or last year
An employee of the sponsor or the study, or a member of their close Family
Participation in another clinical study or taking a to examined drug within the 30 days oft he test phase
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary aim is the clinical healing time of Herpatch Serum in contrast to Acyclovir Creme and Compeed Patches.
- Secondary Outcome Measures
Name Time Method The secondary aim is the subjective view through the patients and the controller of the study during the 10 days of application (1., 2., 4., 6., 8. and 10. day of treatment) of the products Herpatch Serum, Acyclovir Creme and Compeed Patches (SGAT subjects global assessment of therapy) using a scale from 0-10, with 0 = no as an answer and 10 = perfect as an answer.